Literature DB >> 3538918

Placental alkaline phosphatase immunoreactivity in testicular germ-cell neoplasms.

J C Manivel, J Jessurun, M R Wick, L P Dehner.   

Abstract

We analyzed the sensitivity of a polyclonal antibody to placental alkaline phosphatase (PLAP) in labelling testicular germ-cell neoplasms, by utilizing the peroxidase-antiperoxidase technique. The immunoreactivity of 89 germ-cell tumors for PLAP was as follows: 98% of cases with seminomatous elements were PLAP-positive; 97% of embryonal carcinomas and 85% of endodermal sinus tumors also showed reactivity. Cytotrophoblastic cells were focally immunoreactive in one of two cases with choriocarcinomatous elements. Staining for PLAP was strongest and most diffuse in seminomas. Intratubular germ-cell neoplasia (ITGCN) or carcinoma in situ was present in 53 (84%) of 63 specimens that had adjacent seminiferous tubules available for evaluation; PLAP was demonstrated in 98% of these. In addition, the germ-cell elements in 11 gonadoblastomas were immunoreactive for PLAP. One of 17 cases of undescended testes had ITGCN that was also strongly immunoreactive, but the remaining 16 cases were negative. Five dysgenetic gonads without ITGCN were studied, and one was immunoreactive for PLAP. Three testicular biopsy specimens from infertile men without ITGCN were PLAP-negative. Our findings indicate that PLAP is a highly sensitive marker for seminomas, for the majority of embryonal carcinomas and endodermal sinus tumors of the testis, and for ITGCN.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3538918     DOI: 10.1097/00000478-198701000-00003

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  12 in total

Review 1.  Microinvasive germ cell tumor of the testis.

Authors:  Finn Edler von Eyben; Grete Krag Jacobsen; Rolf Inge Skotheim
Journal:  Virchows Arch       Date:  2005-06-21       Impact factor: 4.064

Review 2.  Testis-preserving strategies in testicular germ cell tumors and germ cell neoplasia in situ.

Authors:  Pia Paffenholz; David Pfister; Axel Heidenreich
Journal:  Transl Androl Urol       Date:  2020-01

Review 3.  Diagnosis and treatment of patients with testicular germ cell cancer.

Authors:  J T Hartmann; L Kanz; C Bokemeyer
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

Review 4.  Morphological approach to tumours of the testis and paratestis.

Authors:  Robert E Emerson; Thomas M Ulbright
Journal:  J Clin Pathol       Date:  2007-02-16       Impact factor: 3.411

Review 5.  Placental-like alkaline phosphatase in seminoma.

Authors:  K Koshida; B Wahren
Journal:  Urol Res       Date:  1990

6.  Intratubular germ cell neoplasms of the testis and bilateral testicular tumors: clinical significance and management options.

Authors:  Michael C Risk; Timothy A Masterson
Journal:  Indian J Urol       Date:  2010 Jan-Mar

7.  Intratubular germ cell neoplasia in a man with ambiguous genitalia, 45,X/46,XY mosaic karyotype, and Y chromosome microdeletions.

Authors:  Athanasios D Papanikolaou; Dimitrios G Goulis; Chariklia Giannouli; Christina Gounioti; John N Bontis; John Papadimas
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

8.  Heterogeneity of expression of immunohistochemical tumour markers in testicular carcinoma in situ: pathogenetic relevance.

Authors:  E Rajpert-De Meyts; M Kvist; N E Skakkebaek
Journal:  Virchows Arch       Date:  1996-06       Impact factor: 4.064

9.  KIT mutations are common in testicular seminomas.

Authors:  Kathleen Kemmer; Christopher L Corless; Jonathan A Fletcher; Laura McGreevey; Andrea Haley; Diana Griffith; Oscar W Cummings; Cecily Wait; Ajia Town; Michael C Heinrich
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

10.  Spermatocytic seminoma at the National Institute of Oncology in Morocco.

Authors:  Ghizlane G Raiss; Marwane M Benatiya Andaloussi; Soundouss S Raissouni; Hind H Mrabti; Hassan H Errihani
Journal:  BMC Res Notes       Date:  2011-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.